Cell Metabolism
Volume 23, Issue 3, 8 March 2016, Pages 405-412
Journal home page for Cell Metabolism

Review
New Therapeutic Approaches to the Treatment of Dyslipidemia

https://doi.org/10.1016/j.cmet.2016.01.005Get rights and content
Under an Elsevier user license
open archive

Dyslipidemia is a risk factor for atherosclerotic cardiovascular disease (ASCVD). Abundant data indicate that low-density lipoproteins (LDL) are causal for ASCVD; a new class of LDL-lowering medicines, the PCSK9 inhibitors, will address much unmet medical need. Human genetics suggest that triglyceride-rich lipoproteins (TRL) are pro-atherogenic and have pointed to a number of protein regulators of lipoprotein lipase activity that are candidates for therapeutic targeting. Finally, high-density lipoprotein (HDL) cholesterol does not appear to be causally associated with protection from ASCVD, reinforced by the failure of three CETP inhibitors in CV outcome trials, but HDL function remains of interest.

Cited by (0)